Results 41 to 50 of about 57,324 (252)

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

The recent advancement of TCR-T cell therapies for cancer treatment

Acta Biochimica et Biophysica Sinica
Adoptive cell therapies involve infusing engineered immune cells into cancer patients to recognize and eliminate tumor cells. Adoptive cell therapy, as a form of living drug, has undergone explosive growth over the past decade.
Zhao Xiang, Shao Shuai, Hu Lanxin
doaj   +1 more source

Generation of TCRα-transduced T cells for adoptive transfer therapy of salmonellosis in mice

STAR Protocols, 2021
Summary: Adoptive transfer therapy has great potential to treat diseases such as cancer as well as autoimmune and infectious diseases. Identification of chain-centric T cell receptors (TCRs) with the dominant-active antigen-specific α-chains (TCRα) can ...
Anastasiia Kalinina, Alexandra Bruter, Ludmila Nesterenko, Ludmila Khromykh, Dmitry Kazansky   +4 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes

OncoImmunology, 2021
The optimization of adoptive transfer approaches of anti-tumor T cells requires both the functional improvement of the injected T cells and the modulation of the tumor microenvironment, favoring the recruitment of these T cells and their activation.
L Marotte, M Capitao, C Deleine, T Beauvais, G Cadiou, J. Perrin, M Chérel, E Scotet, Y Guilloux, F Bruchertseifer, A Morgenstern, A Jarry, J. Gaschet, N Labarriere   +13 more
doaj   +1 more source

Adoptive T cell therapy for cancer in the clinic [PDF]

Journal of Clinical Investigation, 2007
The transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease.
openaire   +2 more sources

Gene Engineering T Cells with T-Cell Receptor for Adoptive Therapy

, 2022
AbstractPrior to clinical testing of adoptive T-cell therapy with T-cell receptor (TCR)-engineered T cells, TCRs need to be retrieved, annotated, gene-transferred, and extensively tested in vitro to accurately assess specificity and sensitivity of target recognition.
Kortleve, Dian, van Brakel, Mandy, Wijers, Rebecca, Debets, Reno, Hammerl, Dora   +4 more
openaire   +3 more sources

Tracking the T‐cell repertoire after adoptive therapy [PDF]

Clinical & Translational Immunology, 2017
In recent years, there has been increased interest in using immunotherapy to treat cancer. Adoptive T-cell therapy (ACT) involves the isolation and expansion of tumour-specific T cells in vitro. Large numbers of tumour-specific T cells are then infused back into cancer patients to provide a substantial ‘boost’ to anti-cancer immunity.
Watkins, Thomas S., Miles, John J.
openaire   +6 more sources